The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“The intratumoral heterogeneity of tumors provides a template for the clonal selection and expansion of target-negative tumor cells [13] and is a known mechanism of acquired resistance to targeted therapies [14, 15].”
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“overexpression of MDR1), prediction of disease progression and likelihood of relapse [1, 2].”
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
Advances and Challenges of Liposome Assisted Drug Delivery
Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00286 · Cited by 2,632
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Self-citationPhenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742
Multicellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Choosing the right cell line for breast cancer research
Holliday, D. L., & Speirs, V. (2011) · Breast Cancer Research · doi:10.1186/bcr2889 · Cited by 1,541
Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 2)
Honary, S., & Zahir, F. (2013) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v12i2.20 · Cited by 1,309
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citationMaeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Effect of Zeta Potential on the Properties of Nano-Drug Delivery Systems - A Review (Part 1)
Honary, S., & Zahir, F. (2013) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v12i2.19 · Cited by 1,138
Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,102
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos‐Hoff, M. H., PETERSEN, O. W., et al. (2008) · eScholarship (California Digital Library) · Cited by 1,039
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 831
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G. T., Shalaby, R., Baselga, J. M., Shao, Y. Y., Nielsen, U. B., Marks, J. D., Moore, D. H., et al. (2002) · Clinical Cancer Research · Cited by 766
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work
Gillies, R. J., Verduzco, D., & Gatenby, R. A. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3298 · Cited by 684
Microvascular permeability of normal and neoplastic tissues
Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622
Understanding and targeting cancer stem cells: therapeutic implications and challenges
Chen, K., Huang, Y.-H., & Chen, J.-L. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.27 · Cited by 608
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Self-citationDynamics of genomic clones in breast cancer patient xenografts at single-cell resolution
Eirew, P., Steif, A., Khattra, J., Ha, G., Yap, D., Farahani, H., Gelmon, K., Chia, S., Mar, C., Wan, A., et al. (2015) · Nature · doi:10.1038/nature13952 · Cited by 598
In search of breast cancer culprits: suspecting the suspected and the unsuspected.
Subik, K., Lee, J.-F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., Hung, M., Bonfiglio, T. A., Hicks, D. G., et al. (2008) · PubMed Central · Cited by 577
Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D. M., Peters, A. M., Vile, R. G., & Stewart, J. S. W. (2001) · PubMed · Cited by 575
Subik, K., Lee, J.-F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., Hung, M.-C., Bonfiglio, T., Hicks, D. G., et al. (2010) · Breast Cancer: Basic and Clinical Research · doi:10.1177/117822341000400004 · Cited by 573
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Controlled Vesicle Self-Assembly in Microfluidic Channels with Hydrodynamic Focusing
Jahn, A., Vreeland, W. N., Gaitan, M., & Locascio, L. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0318030 · Cited by 537
3D cell culture systems modeling tumor growth determinants in cancer target discovery
Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.03.001 · Cited by 478
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals
Ying, X., Wen, H., Lu, W.-L., Du, J., Guo, J., Tian, W., Men, Y., Zhang, Y., Li, R.-J., Yang, T.-Y., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.020 · Cited by 447
Liposome Technology for Industrial Purposes
Wagner, A., & Vorauer-Uhl, K. (2011) · Journal of Drug Delivery · doi:10.1155/2011/591325 · Cited by 435
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
Schnitt, S. J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.33 · Cited by 419
Pickl, M., & Ries, C. H. (2009) · Oncogene · doi:10.1038/onc.2008.394 · Cited by 401
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.012 · Cited by 398
Self-citationTargeted therapies in breast cancer: New challenges to fight against resistance
Masoud, V., & Pagès, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.120 · Cited by 357
Tumor targeting using anti-her2 immunoliposomes
Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., & Benz, C. C. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00315-7 · Cited by 335
Shaheen, R. M., Davis, D. W., Liu, W., Zebrowski, B. K., Wilson, M. R., Bucana, C. D., McConkey, D. J., McMahon, G., & Ellis, L. M. (1999) · PubMed · Cited by 334
Weigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
Mouse models of metastasis: progress and prospects
Gómez-Cuadrado, L., Tracey, N., Ma, R., Qian, B., & Brunton, V. G. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030403 · Cited by 301
Uster, P. S., Allen, T. M., Daniel, B. E., Mendez, C. J., Newman, M. S., & Zhu, G. Z. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00452-8 · Cited by 298
Laverman, P., Carstens, M. G., Boerman, O. C., Th. M. Dams, E., Oyen, W. J. G., van Rooijen, N., Corstens, F. H. M., & Storm, G. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29419-2 · Cited by 298
Self-citationLukyanov, A. N., Elbayoumi, T. A., Chakilam, A. R., & Torchilin, V. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.007 · Cited by 294
Hansen, A. E., Petersen, A. L., Henriksen, J. R., Boerresen, B., Rasmussen, P., Elema, D. R., Rosenschöld, P. M. A., Kristensen, A. T., Kjær, A., & Andresen, T. L. (2015) · ACS Nano · doi:10.1021/acsnano.5b01324 · Cited by 277
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E., Ariazi, J., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776173483 · Cited by 255
Ligand-Targeted Liposomes for Cancer Treatment
Sapra, P., Tyagi, P., & Allen, T. (2005) · Current Drug Delivery · doi:10.2174/156720105774370159 · Cited by 246
Gao, W., Xiang, B., Meng, T.-T., Liu, F., & Qi, X.-R. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.014 · Cited by 238
Cancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Self-citationEstrogen Receptors as Therapeutic Targets in Breast Cancer
Ariazi, E. A., & Jordan, V. C. (2008) · Methods and Principles in Medicinal Chemistry · doi:10.1002/9783527623297.ch5 · Cited by 230
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
Diversity of cell-mediated adhesions in breast cancer spheroids
Ivascu, A., & Kubbies, M. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1403 · Cited by 229
A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay
Friedrich, J., Eder, W., Castaneda, J., Doss, M., Huber, E., Ebner, R., & Kunz-Schughart, L. A. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107306839 · Cited by 227
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers
Saul, J. M., Annapragada, A. V., & Bellamkonda, R. V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.028 · Cited by 227
McCarty, O. J. T., Mousa, S. A., Bray, P. F., & Konstantopoulos, K. (2000) · Blood · doi:10.1182/blood.v96.5.1789 · Cited by 223
Angelova, A., Garamus, V. M., Angelov, B., Tian, Z., Li, Y., & Zou, A. (2017) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2017.04.006 · Cited by 211
Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective
Moeller, L. C., & Führer, D. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-12-0219 · Cited by 184
Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy
Batist, G., Barton, J., Chaikin, P., Swenson, C., & Welles, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1739 · Cited by 179
The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications
Velasco-Velázquez, M. A., Popov, V. M., Lisanti, M. P., & Pestell, R. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.005 · Cited by 178
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen, J., Peters, H. A., van Putten, W. L., Look, M. P., Pappot, H., Rønne, E., Danø, K., Klijn, J. G. M., Brünner, N., & Foekens, J. A. (1995) · PubMed · Cited by 173
Clark, A. J., Wiley, D. T., Zuckerman, J. E., Webster, P., Chao, J., Lin, J., Yen, Y., & Davis, M. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603018113 · Cited by 168
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Sagiv, E., Starr, A., Rozovski, U., Khosravi, R., Altevogt, P., Wang, T., & Arber, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6463 · Cited by 163
Clinical Studies of Liposome-Encapsulated Doxorubicin
Gabizon, A., Isacson, R., Libson, E., Kaufman, B., Uziely, B., Catane, R., Ben-Dor, C. G., Rabello, E., Cass, Y., Peretz, T., et al. (1994) · Acta Oncologica · doi:10.3109/02841869409083948 · Cited by 160
Development of ligand-targeted liposomes for cancer therapy
Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., & Drummond, D. C. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.4.335 · Cited by 157
Targeting EGFR in Pancreatic Cancer Treatment
Troiani, T., Martinelli, E., Capasso, A., Morgillo, F., Orditura, M., Vita, F. D., & Ciardiello, F. (2012) · Current Drug Targets · doi:10.2174/138945012800564158 · Cited by 146
Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment
Herrmann, D., Conway, J. R. W., Vennin, C., Magenau, A., Hughes, W. E., Morton, J. P., & Timpson, P. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu108 · Cited by 145
Kluza, E., van der Schaft, D. W. J., Hautvast, P. A. I., Mulder, W. J. M., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., & Nicolay, K. (2009) · Nano Letters · doi:10.1021/nl902659g · Cited by 144
Espelin, C. W., Leonard, S. C., Geretti, E., Wickham, T. J., & Hendriks, B. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1518 · Cited by 135
Spatiotemporal Targeting of a Dual-Ligand Nanoparticle to Cancer Metastasis
Doolittle, E., Peiris, P. M., Doron, G., Goldberg, A. L., Tucci, S. T., Rao, S. P., Shah, S., Sylvestre, M., Govender, P., Turan, O., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b01552 · Cited by 125
Lale, S. V., Girija, A. R., Aravind, A., Kumar, D. S., & Koul, V. (2014) · Biomacromolecules · doi:10.1021/bm5001263 · Cited by 125
Solomayer, E. F., Becker, S., Becker‐Pergola, G., Bachmann, R., Krämer, B., Vogel, U. F., Neubauer, H. J., Wallwiener, D. R., Huober, J., & Fehm, T. N. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9147-y · Cited by 122
Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome
Garg, K., Maurer‐Granofszky, M., Griss, J., Brüggen, M., Wolf, I. H., Wagner, C., Willi, N., Mertz, K. D., & Wagner, S. N. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.022 · Cited by 120
Liposomes targeted via two different antibodies: Assay, B-cell binding and cytotoxicity
Laginha, K. M., Mumbengegwi, D. R., & Allen, T. M. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.007 · Cited by 119
Szebeni, J., & Storm, G. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.06.177 · Cited by 111
Self-citationGuo, F., Yu, M., Wang, J., Tan, F., & Li, N. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b06552 · Cited by 111
Gabizón, A., Isacson, R., Rosengarten, O. S., Tzemach, D., Shmeeda, H., & Sapir, R. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0525-5 · Cited by 110
Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
Venkatesan, S., & Swanton, C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158930 · Cited by 107
Pyke, C., Ralfkiaer, E. M., Rønne, E., Høyer‐Hansen, G., Kirkeby, L. T., & Danø, K. (1994) · Histopathology · doi:10.1111/j.1365-2559.1994.tb01291.x · Cited by 106
QIN, L., WANG, C.-Z., Fan, H., Zhang, C., Zhang, H., Lv, M., & Cui, S. (2014) · Oncology Letters · doi:10.3892/ol.2014.2449 · Cited by 106
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
Zhao, M., Ding, X., Shen, J.-Y., Zhang, X.-P., Ding, X., & Xu, B. (2017) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1600303 · Cited by 102
Tang, Y., Soroush, F., Sheffield, J. B., Wang, B., Prabhakarpandian, B., & Kiani, M. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-09815-9 · Cited by 102
Cheng, W., & Allen, T. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903579963 · Cited by 90
Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer
LeBeau, A. M., Duriseti, S., Murphy, S. T., Pepin, F., Hann, B. C., Gray, J. W., VanBrocklin, H. F., & Craik, C. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3526 · Cited by 90
Jo, M., Eastman, B. M., Webb, D. L., Stoletov, K. V., Klemke, R. L., & Gonias, S. L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1936 · Cited by 89
Sharma, G., Modgil, A., Zhong, T., Sun, C., & Singh, J. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1242-x · Cited by 87
Expression of CD44 in pancreatic cancer and its significance.
Li, X.-P., Zhang, X.-W., Zheng, L., & Guo, W.-J. (2015) · Europe PMC (PubMed Central) · Cited by 82
Gao, H., Yang, Z. H., Zhang, S., Pang, Z., Liu, Q., & Jiang, X. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.11.003 · Cited by 79
The importance of animal models in tumor immunity and immunotherapy
Budhu, S., Wolchok, J. D., & Merghoub, T. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.008 · Cited by 78
Assénat, E., Azria, D., Mollévi, C., Guimbaud, R., Tubiana-Mathieu, N., Smith, D. M., Delord, J., Samalin, E., Portales, F., Larbouret, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3473 · Cited by 77
Nanomedicine for The Management of Lung and Blood Diseases
Buxton, D. B. (2009) · Nanomedicine · doi:10.2217/nnm.09.8 · Cited by 76
Mechanisms of tumor cell resistance to the current targeted-therapy agents
Khamisipour, G., Jadidi‐Niaragh, F., Jahromi, A. S., Zandi, K., & Hojjat‐Farsangi, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5059-1 · Cited by 76
Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Kikuchi, H., & Ishihara, H. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.09.047 · Cited by 75
Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles
Mizrahy, S., Goldsmith, M., Ben‐Arye, S. L., Kisin‐Finfer, E., Redy‐Keisar, O., Srinivasan, S., Shabat, D., Godin, B., & Peer, D. (2014) · Nanoscale · doi:10.1039/c3nr06102g · Cited by 74
Survival Outcomes in Breast Cancer Patients With Low Estrogen/Progesterone Receptor Expression
Balduzzi, A., Bagnardi, V., Rotmensz, N., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.10.019 · Cited by 71
Zhao, Y., Wang, C., Wang, L., Yang, Q., Tang, W., She, Z., & Deng, Y. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.023 · Cited by 71
Howard, C. B., Fletcher, N. L., Houston, Z. H., Fuchs, A. V., Boase, N. R. B., Simpson, J. D., Raftery, L. J., Ruder, T., Jones, M. L., de Bakker, C. J., et al. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600263 · Cited by 70
Self-citationZhang, B., Zhang, Y., & Yu, D. (2016) · Oncology Reports · doi:10.3892/or.2016.5298 · Cited by 69
Far Beyond the Usual Biomarkers in Breast Cancer: A Review
Pultz, B. D. A., da Luz, F. A. C., de Faria, P. R., Oliveira, A. P. L., de Araújo, R. A., & Silva, M. J. B. (2014) · Journal of Cancer · doi:10.7150/jca.8925 · Cited by 67
Li, L., & Lu, Y. (2011) · Journal of Cancer · doi:10.7150/jca.2.458 · Cited by 67
Siegler, E. L., Kim, Y. J., & Wang, P. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2016.08.002 · Cited by 65
Dual HER2-targeted approaches in HER2-positive breast cancer
Ahn, E. R., & Vogel, C. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1781-y · Cited by 64
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning, Y. M., He, K., Dagher, R. N., et al. (2007) · PubMed · Cited by 64
Guiding Principles in The Design of Ligand-Targeted Nanomedicines
Wang, X., Galliford, C. V., & Low, P. S. (2014) · Nanomedicine · doi:10.2217/nnm.13.175 · Cited by 63
Zhang, Q., Lu, L., Zhang, L., Shi, K., Cun, X., Yang, Y., Liu, Y., Gao, H., & He, Q. (2016) · Scientific Reports · doi:10.1038/srep19800 · Cited by 62
Croucher, D. R., Iconomou, M., Hastings, J. F., Kennedy, S. P., Han, J. Z. R., Shearer, R. F., McKenna, J. A., Wan, A., Lau, J., Aparicio, S. A. J. R., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aaf0793 · Cited by 61
Self-citationCD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
Boulbés, D. R., Chauhan, G. B., Jin, Q., Bartholomeusz, C., & Esteva, F. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3414-3 · Cited by 59
Chiu, G. N. C., Edwards, L., Kapanen, A. I., Malinen, M. M., Dragowska, W. H., Warburton, C., Chikh, G., Fang, K. Y. Y., Tan, S., Sy, J., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0159 · Cited by 59
Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies
Bahrami, A., Khazaei, M., Bagherieh, F., Ghayour‐Mobarhan, M., Maftouh, M., Hassanian, S. M., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25798 · Cited by 53
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
Menyhárt, O., Santarpia, L., & Győrffy, B. (2015) · Current Cancer Drug Targets · doi:10.2174/156800961508151001101742 · Cited by 48
Valent, P. (2007) · PubMed Central · Cited by 47
Vamvakidou, A. P., Mondrinos, M. J., Petushi, S., Garcia, F. U., Lelkes, P. I., & Tözeren, A. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106296482 · Cited by 45
Radionuclide imaging of liposomal drug delivery
van der Geest, T., Laverman, P., Metselaar, J. M., Storm, G., & Boerman, O. C. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1205584 · Cited by 45
Self-citationEPR or no EPR? The billion-dollar question
Wang, A. Z. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8108 · Cited by 44 · cited 1×
“tumor types and is not observed for all solid tumors [140, 141].”
Senavirathna, L. K., Fernando, R., Maples, D., Zheng, Y., Polf, J., & Ranjan, A. (2013) · Theranostics · doi:10.7150/thno.6381 · Cited by 43
Targeting ligand–receptor interactions for development of cancer therapeutics
Kim, J. W., & Cochran, J. R. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.03.010 · Cited by 43
Mapping the Pathways of Resistance to Targeted Therapies
Wood, K. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1248 · Cited by 42
Double Click: Dual Functionalized Polymeric Micelles with Antibodies and Peptides
Chan, D. P. Y., Owen, S. C., & Shoichet, M. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300511a · Cited by 39
Rabenhold, M., Steiniger, F., Fahr, A., Kontermann, R. E., & Rüger, R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.022 · Cited by 35
Lee, H. W., Kook, Y.-M., Lee, H. J., Park, H., & Koh, W. (2014) · RSC Advances · doi:10.1039/c4ra12269k · Cited by 35
Nielsen, A., Scarlett, C. J., Samra, J. S., Gill, A. J., Li, Y., Allen, B., & Smith, R. C. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03531.x · Cited by 33
Lopes, G. D. L., Jr., Glück, S., Avancha, K. K. V. R., & Montero, A. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2326-8 · Cited by 31
Thyroid Stimulating Hormone Receptor
Tuncel, M. (2017) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/2017.26.suppl.10 · Cited by 30
Rehman, S. S. U., Lim, K., & Wang‐Gillam, A. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1174581 · Cited by 28
Pearce, A. K., Fuchs, A. V., Fletcher, N. L., & Thurecht, K. J. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1945-x · Cited by 28
Self-citationOussoren, C., & Storm, G. (1999) · Journal of Liposome Research · doi:10.3109/08982109909018655 · Cited by 25
Self-citationLudyga, N., Anastasov, N., Rosemann, M., Seiler, J., Lohmann, N., Braselmann, H., Mengele, K., Schmitt, M., Höfler, H., & Aubele, M. M. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0378 · Cited by 25
Karaçalı, B., Vamvakidou, A. P., & Tözeren, A. (2007) · BMC Medical Imaging · doi:10.1186/1471-2342-7-7 · Cited by 23
CD109 Overexpression in Pancreatic Cancer Identified by Cell-Surface Glycoprotein Capture
Haun, R. S., & Fan, C. Y. (2014) · Journal of Proteomics & Bioinformatics · doi:10.4172/jpb.s10-003 · Cited by 21
Szebeni, J., Muggia, F. M., & Barenholz, Y. (2016) · Frontiers in nanobiomedical research · doi:10.1142/9789813140455_0010 · Cited by 15
Gao, H., Hu, Y., Xiong, Y., Zhang, S., Yang, J., Yu, L., & Jiang, X. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140425102937 · Cited by 9
Rafts, Nanoparticles and Neural Disease
Gulati, V., & Wallace, R. (2012) · Nanomaterials · doi:10.3390/nano2030217 · Cited by 5
Editorial: Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps
Shafaee, M. N., & Ellis, M. J. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw307 · Cited by 3
Cited by
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · doi:10.20944/preprints201810.0507.v1 · Cited by 605
Exosomes and Exosome-Inspired Vesicles for Targeted Drug Delivery
Antimisiaris, S. G., Mourtas, S., & Marazioti, A. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040218 · Cited by 603
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Li, S., Su, W., Wu, H., Yuan, T., Yuan, C., Liu, J., Deng, G., Gao, X., Chen, Z., Bao, Y., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0540-y · Cited by 424
Metadata
- Authors
- Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 277
- Pages
- 1-13
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2794339309
- Cited by
- 294
- References
- 153
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.